{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T13:36:01Z","timestamp":1774186561592,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.thromres.2018.11.023","type":"journal-article","created":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T16:04:40Z","timestamp":1543075480000},"page":"102-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Effect of P2Y12 inhibitors on thrombus stability and endogenous fibrinolysis"],"prefix":"10.1016","volume":"173","author":[{"given":"Nikolaos","family":"Spinthakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying X.","family":"Gue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manivannan","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Wellsted","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-1451","authenticated-orcid":false,"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.thromres.2018.11.023_bb0005","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.jacc.2017.08.065","article-title":"Arterial thrombus stability: does it matter and can we detect it?","volume":"70","author":"Gorog","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2018.11.023_bb0010","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s11239-018-1641-2","article-title":"Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications","volume":"45","author":"Gorog","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"issue":"7","key":"10.1016\/j.thromres.2018.11.023_bb0015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2018.11.023_bb0020","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.thromres.2018.11.023_bb0025","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2018.11.023_bb0030","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/eurheartj\/ehs300","article-title":"Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease","volume":"34","author":"Sharma","year":"2013","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.thromres.2018.11.023_bb0035","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/nur.20247","article-title":"Considerations in determining sample size for pilot studies","volume":"31","author":"Hertzog","year":"2008","journal-title":"Res. Nurs. Health"},{"issue":"4","key":"10.1016\/j.thromres.2018.11.023_bb0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/pst.185","article-title":"Sample size of 12 per group rule of thumb for a pilot study","volume":"4","author":"Julious","year":"2005","journal-title":"Pharm. Stat."},{"issue":"5","key":"10.1016\/j.thromres.2018.11.023_bb0045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1055\/s-0038-1650374","article-title":"Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow","volume":"75","author":"Barstad","year":"1996","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2018.11.023_bb0050","article-title":"Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2018.11.023_bb0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.thromres.2016.01.026","article-title":"Aspirin has limited ability to modulate shear-mediated platelet activation associated with elevated shear stress of ventricular assist devices","volume":"140","author":"Valerio","year":"2016","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2018.11.023_bb0060","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jacc.2005.02.092","article-title":"Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug","volume":"46","author":"Labarthe","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.thromres.2018.11.023_bb0065","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.mvr.2011.11.007","article-title":"A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process","volume":"83","author":"Hosokawa","year":"2012","journal-title":"Microvasc. Res."},{"issue":"12","key":"10.1016\/j.thromres.2018.11.023_bb0070","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1161\/01.ATV.16.12.1532","article-title":"Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation","volume":"16","author":"Humbert","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.thromres.2018.11.023_bb0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-9560-10-11","article-title":"Development of a perfusion chamber assay to study in real time the kinetics of thrombosis and the antithrombotic characteristics of antiplatelet drugs","volume":"10","author":"Stephens","year":"2012","journal-title":"Thromb. J."},{"issue":"3","key":"10.1016\/j.thromres.2018.11.023_bb0080","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI17864","article-title":"P2Y12 regulates platelet adhesion\/activation, thrombus growth, and thrombus stability in injured arteries","volume":"112","author":"Andre","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.thromres.2018.11.023_bb0085","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/blood-2006-03-006338","article-title":"Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization","volume":"108","author":"Cosemans","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2018.11.023_bb0090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jacc.2005.08.055","article-title":"Dependence of platelet thrombus stability on sustained glycoprotein IIb\/IIIa activation through adenosine 5\u2032-diphosphate receptor stimulation and cyclic calcium signaling","volume":"47","author":"Goto","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2018.11.023_bb0095","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1182\/blood-2006-08-040857","article-title":"Thrombus formation:stability matters","volume":"108","author":"Brass","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.11.023_bb0100","series-title":"Presented at: The 66th Annual Scientific Session & Expo of the American College of Cardiology. March 17\u201319, 2017; Washington, DC","article-title":"Time related benefit of antiplatelet therapy on coronary reperfusion in ST-elevation myocardial infarction (STEMI) patients. Abstract 1296\u2013303","author":"Pepe","year":"2017"},{"issue":"5","key":"10.1016\/j.thromres.2018.11.023_bb0105","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10557-015-6609-2","article-title":"Cardioprotective properties of the platelet P2Y12 receptor inhibitor, cangrelor: protective in diabetics and reliant upon the presence of blood","volume":"29","author":"Bell","year":"2015","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"3","key":"10.1016\/j.thromres.2018.11.023_bb0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1074248412467692","article-title":"Platelet P2Y\u2081\u2082 blockers confer direct postconditioning-like protection in reperfused rabbit hearts","volume":"18","author":"Yang","year":"2013","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.thromres.2018.11.023_bb0115","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1161\/01.ATV.19.10.2281","article-title":"ADP receptors and clinical bleeding disorders","volume":"19","author":"Cattaneo","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.thromres.2018.11.023_bb0120","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/FJC.0000000000000076","article-title":"Signaling via P2Y12 may be critical for early stabilization of platelet aggregates","volume":"63","author":"Speich","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"5","key":"10.1016\/j.thromres.2018.11.023_bb0125","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0049-3848(93)90241-F","article-title":"Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets","volume":"72","author":"Torr-Brown","year":"1993","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2018.11.023_bb0130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrd2957","article-title":"Antiplatelet therapies for the treatment of cardiovascular disease","volume":"9","author":"Michelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.thromres.2018.11.023_bb0135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrcardio.2009.10","article-title":"Antiplatelet drug \u2018resistance\u2019. Part 1: mechanisms and clinical measurements","volume":"6","author":"Sweeny","year":"2009","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.thromres.2018.11.023_bb0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.thromres.2006.01.019","article-title":"Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study","volume":"119","author":"Malinin","year":"2007","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2018.11.023_bb0145","series-title":"Plavix (Clopidogrel Bisulfate) Tablets. Approved Prescribing Information. Updated Dec 2013. [Internet]","year":"2013"},{"issue":"19","key":"10.1016\/j.thromres.2018.11.023_bb0150","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"Cannon","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.thromres.2018.11.023_bb0155","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur. Heart J."},{"issue":"25","key":"10.1016\/j.thromres.2018.11.023_bb0160","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2018.11.023_bb0165","series-title":"Brilinta (Ticagrelor) Tablets. Approved Prescribing Information. Updated Mar 29, 2013. [Internet]","year":"2013"},{"issue":"1","key":"10.1016\/j.thromres.2018.11.023_bb0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist","volume":"50","author":"Akers","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.thromres.2018.11.023_bb0175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2005-869525","article-title":"Preclinical and clinical studies with selective reversible direct P2Y12 antagonists","volume":"31","author":"van Giezen","year":"2005","journal-title":"Semin. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.thromres.2018.11.023_bb0180","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0037-1615596","article-title":"Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes","volume":"85","author":"Storey","year":"2001","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2018.11.023_bb0185","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/0953710021000024402","article-title":"Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease","volume":"13","author":"Storey","year":"2002","journal-title":"Platelets"},{"issue":"2","key":"10.1016\/j.thromres.2018.11.023_bb0190","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ahj.2007.04.014","article-title":"Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis","volume":"154","author":"Snoep","year":"2007","journal-title":"Am. Heart J."},{"issue":"2","key":"10.1016\/j.thromres.2018.11.023_bb0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.amjcard.2009.03.022","article-title":"Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy","volume":"104","author":"Ben-Dor","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.thromres.2018.11.023_bb0200","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12959-015-0069-6","article-title":"Global thrombosis test - a possible monitoring system for the effects and safety of dabigatran","volume":"13","author":"Otsui","year":"2015","journal-title":"Thromb. J."},{"issue":"19","key":"10.1016\/j.thromres.2018.11.023_bb0205","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jacc.2010.01.033","article-title":"Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction","volume":"55","author":"Saraf","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2018.11.023_bb0210","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehy565.2151","article-title":"Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study","author":"Farag","year":"2018","journal-title":"Eur. Heart J."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818306285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818306285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T03:46:06Z","timestamp":1717213566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384818306285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":42,"alternative-id":["S0049384818306285"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.11.023","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of P2Y12 inhibitors on thrombus stability and endogenous fibrinolysis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}